Infanrix–polio+hib

Diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine, the active ingredient in Infanrix–polio+hib, is a vaccine presented as an injectable solution for intramuscular use. It induces protective immunity against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b in infants and young children.

GNH USA supplies Infanrix–polio+hib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix–polio+hib is a combination vaccine that targets several bacterial and viral diseases in the pediatric immunisation schedule. - Diphtheria: prevents the life‑threatening toxin‑mediated disease. - Tetanus: protects against the neurotoxin that causes muscle rigidity and spasms. - Pertussis: reduces severe coughing episodes and complications in infants. - Poliomyelitis: provides immunity against poliovirus types 1, 2 and 3. - Haemophilus influenzae type b infection: prevents meningitis, pneumonia and epiglottitis caused by Hib.

The following adverse reactions have been reported after administration of Infanrix–polio+hib.

Common Side Effects: - Pain at the injection site: mild to moderate discomfort. - Redness or swelling: localized erythema. - Fever: low‑grade temperature rise within 24‑48 hours. - Irritability or crying: especially in infants. - Loss of appetite: temporary reduction in feeding. - Mild rash: transient skin eruption.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: febrile or non‑febrile convulsions. - High fever (>40 °C): may be accompanied by lethargy. - Hypotonic‑hyporesponsive episode: reduced muscle tone and responsiveness. - Encephalopathy: rare inflammation of the brain. - Persistent crying lasting >3 hours: may indicate a serious reaction.

Before administering Infanrix–polio+hib, consider the following precautions. - Prior vaccine history: verify no severe allergic reaction to any component. - Acute illness: postpone vaccination if the child has a moderate or severe febrile illness. - Immunocompromised status: assess risk‑benefit, as response may be reduced. - Seizure history: monitor closely after injection. - Concomitant medications: avoid simultaneous use of immunosuppressants unless medically indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that affect the immune system.

Major Interactions (Avoid): - Live attenuated vaccines: do not administer concurrently; separate by at least 4 weeks. - Severe allergic reaction to any component: contraindicates use.

Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: may diminish vaccine‑induced antibody response. - Antipyretics (e.g., acetaminophen) given prophylactically: could blunt immune response. - Corticosteroids at immunosuppressive doses: may reduce immunogenicity. - Blood products administered within 48 hours: potential interference with antibody formation.